Dr. Reddy's subsidiary hits the pause button on drug development for psoriasis

A biotech subsidiary of the India-based pharma company Dr. Reddy’s Laboratories is halting the development of a psoriasis drug.

In an announcement to the National Stock Exchange of India on Friday, the biotech Aurigene Oncology posted the results of its Phase II study of the oral candidate AUR101 in patients with moderate to severe plaque psoriasis.